L.L.C. is a biotechnology company with innovative technologies
discovered and developed by leading glycobiologists Paul DeAngelis,
Ph.D. and Paul Weigel, Ph.D. The company was formed to commercialize
unique recombinant technologies for producing Hyaluronic Acid
(HA), an important biomolecule for many healthcare and cosmetic
strong intellectual property portfolio of 35 issued and 49
pending patents, the IP and scientific expertise of Hyalose
meet today’s market demands for highly controlled HA
production. Hyalose technologies also address growing and
emerging needs of the fuller spectrum of glycoengineering,
including medical research and drug development. Hyalose is
poised to meet the growing market opportunities of tomorrow.
Markets for Hyalose Technologies
Acid (HA) is a naturally occurring sugar polymer (a member
of the glycosaminoglycan, or GAG family) that may exist as
short or long chains of the same repeating sugar unit. HA
is currently used in multiple markets:
Biomaterials for osteoarthritis
drug and medical device formulation
market for all current applications exceeds $1.7 billion,
and these and other emerging HA markets are expected to grow
to more than $2 billion over the next five years.
also provides competitive advantages to a broader market of
glycoengineering, including tissue engineering, estimated
to be $15 billion annually; and medical device coatings, estimated
at $4.2 billion and predicted to grow to more than $5 billion
of Hyalose Technologies
is produced by extraction, either from animal by-products
or from bacteria. These must be purified to obtain the desired
material for a particular application. During the extraction
procedures, care must be taken not to co-purify pathogens
or detrimental factors commonly found in the source material
(e.g., prions, antigens, allergans, or bacterial toxins).
Hyalose innovation includes superior processes to produce:
of a defined polymer length and content, enabling a high
of control of functionality.
HA from a Generally Regarded As Safe (GRAS) bacterial source.
advantages promise to revolutionize existing HA production
and product specialization, as well as to spur further innovation
in the rapidly growing field of glycoengineering.
Combined Technology Assets
sister companies, Choncept, L.L.C., and Heparinex, L.L.C.,
offer related technology and products for additional GAG polymers
including chondroitin and heparin. Both chondroitin and heparin
are important biopolymers for healthcare, cosmetics, and biomedical
research. The combined assets of these companies offer market
leaders a means to boost present revenue and market share,
as well as enabling continual, long-term glycoengineering
innovation for the future.